Cancer Immunotherapy News and Research

RSS

Combined treatment prolongs survival in mouse models of malignant mesothelioma

Combined treatment with two cancer immunotherapy drugs - one a novel immune modulator and one that focuses and activates the antitumor immune response - significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.

2 Apr 2018

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

American Gene Technologies receives second immuno-oncology patent

American Gene Technologies International Inc., a leading gene and cell therapy company, today announced receipt of a second immuno-oncology patent on the stimulation of gamma delta T cells for treating solid tumors in epithelial cancers.

20 Mar 2018

Novel oncolytic virus expressing BiTE molecule elicits T cell-mediated killing of tumor cells

In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.

13 Mar 2018

Johns Hopkins researchers invent new class of immunotherapy drugs to fight cancer

Johns Hopkins researchers have invented a new class of cancer immunotherapy drugs that are more effective at harnessing the power of the immune system to fight cancer.

2 Mar 2018

Virus-like particle could translate into new vaccine for cancer treatment

Michigan State University scientists are engineering a virus-like particle, known as Qβ, that will generate anti-cancer immune responses in the body and potentially be used as a new vaccine for the treatment of cancer.

2 Mar 2018

Rare immune cell may prove to be potent weapon in fighting against cancer

One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

23 Feb 2018

Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism

Novel bifunctional immunotherapeutic agents have been developed that, as well as deactivating key immune checkpoints,deactivate the tumor's protective response.

23 Feb 2018

Oncolytic virus alerts the immune system to attack tumors

A new UC San Francisco study has shown that a cancer-killing virus currently in clinical trials may function as a cancer vaccine - in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus-infected region.

14 Feb 2018

Molecular 'magnets' could help develop better immunotherapies for cancer patients

Chemicals that attract specialized immune cells toward tumors could be used to develop better immunotherapies for cancer patients, according to new research published in Cell.

9 Feb 2018

Two bacterial species collaborate to drive development of colon cancers

Patients with an inherited form of colon cancer harbor two bacterial species that collaborate to encourage development of the disease, and the same species have been found in people who develop a sporadic form of colon cancer, a study led by a Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy research team finds.

1 Feb 2018

UTokyo enters into agreement for developing personalized cancer vaccine

The University of Tokyo entered an agreement for developing a personalized cancer vaccine using a novel method involving the body's immune response.

25 Jan 2018

Patients with rheumatologic disease can safely receive life-saving cancer immunotherapy

In the largest single-center study of patients with rheumatologic diseases who were prescribed modern cancer immunotherapy with what are called immune checkpoint inhibitors, only a minority of patients experienced a flare of their rheumatologic disease or immune-related side effects.

24 Jan 2018

APEIRON to present at Biotech Showcase 2018 in San Francisco

APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced that it will present at Biotech Showcase 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing.

8 Jan 2018

Specific bacteria in the intestines can improve response rate to cancer immunotherapy

In the Jan. 5, 2018 issue of Science, researchers from the University of Chicago Medicine show that specific strains of commensal bacteria – the swarms of microorganisms naturally dwelling in the intestines – can improve the response rate to immunotherapy for patients being treated for advanced melanoma.

5 Jan 2018

Researchers discover genetic mechanism for resistance to immunotherapy drugs

An urgent question for cancer scientists is why immunotherapy achieves dramatic results in some cases but doesn't help most patients.

5 Jan 2018

Higher ‘mutational burden’ of tumors predicts success rate with cancer immunotherapies

The "mutational burden," or the number of mutations present in a tumor's DNA, is a good predictor of whether that cancer type will respond to a class of cancer immunotherapy drugs known as checkpoint inhibitors, a new study led by Johns Hopkins Kimmel Cancer Center researchers shows.

21 Dec 2017

Study findings could lead to less expensive and more effective cancer treatments

The latest generation of cancer treatments spring from the discovery that the human immune system is able to beat the disease. Like Dorothy in "The Wizard of Oz," what research teams around the world have spent decades searching for was right in their own backyard all along.

20 Dec 2017

Research uncovers mechanism implicated in defective function of tumor-associated dendritic cells

A new study from The Wistar Institute revealed the mechanism implicated in the defective function of tumor-associated dendritic cells (DCs), a specialized type of immune cells that expose the antigens on their surface to activate the T cells.

15 Dec 2017

Researchers discover potential regulator essential for killer T cells to reside in tumors

Researchers report the discovery that a protein called "Runx3" programs killer T cells to establish residence in tumors and infection sites.

11 Dec 2017